Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?
| Status: | Recruiting |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 5/5/2014 |
| Start Date: | October 2013 |
| Contact: | Ron Waksman, MD |
| Email: | ron.waksman@medstar.net |
| Phone: | 202-877-5975 |
Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction?
The aim of this observational study is to evaluate the in hospital and 6 month outcomes of
the use of Glycoprotein IIb/IIIa inhibitor eptifibatide as adjunctive therapy in patients
undergoing primary Percutaneous Coronary Intervention for ST-elevation myocardial infarction
in a large tertiary referral center.
It is hypothesized that Glycoprotein IIb/IIIa inhibitor use during primary Percutaneous
Coronary Intervention for ST-elevation myocardial infarction/ acute myocardial infarction is
superior to unfractionated heparin alone or bivalirudin alone. Additionally, after
propensity matching this superiority remains.
the use of Glycoprotein IIb/IIIa inhibitor eptifibatide as adjunctive therapy in patients
undergoing primary Percutaneous Coronary Intervention for ST-elevation myocardial infarction
in a large tertiary referral center.
It is hypothesized that Glycoprotein IIb/IIIa inhibitor use during primary Percutaneous
Coronary Intervention for ST-elevation myocardial infarction/ acute myocardial infarction is
superior to unfractionated heparin alone or bivalirudin alone. Additionally, after
propensity matching this superiority remains.
This is a retrospective, observational, data analysis of approximately 800 patients who
underwent primary Percutaneous Coronary Intervention at our institution since September
2000. Patients will have either received eptifibatide pre-or during Percutaneous Coronary
Intervention or have received no eptifibatide. Patients who received a thrombolytic prior to
Percutaneous Coronary Intervention will be excluded.
This analysis is estimated to take 1-2 months.
underwent primary Percutaneous Coronary Intervention at our institution since September
2000. Patients will have either received eptifibatide pre-or during Percutaneous Coronary
Intervention or have received no eptifibatide. Patients who received a thrombolytic prior to
Percutaneous Coronary Intervention will be excluded.
This analysis is estimated to take 1-2 months.
Inclusion Criteria:
- Underwent Percutaneous Coronary Intervention at Washington Hospital Center since
September 2000
- Either received eptifibatide pre-or during PCI or have received no eptifibatide.
Exclusion Criteria:
- Patients who received a thrombolytic prior to Percutaneous Coronary Intervention.
We found this trial at
1
site
110 Irving St NW
Washington, District of Columbia 20010
Washington, District of Columbia 20010
(202) 877-7000
Washington Hosp Ctr MedStar Washington Hospital Center is a not-for-profit, 926-bed, major teaching and research...
Click here to add this to my saved trials
